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19 Introduction. White matter hyperintensities (WMHs) are one the most common neuroimaging finding in patients
20 with bipolar disorder (BD). It has been suggested that WMHs are associated with impaired insight in schizophrenia
21 and schizoaffective patients; however, the relationship between insight and WMHs in BD type I has not been directly
22 investigated.
23
24 Methods. Patients with BD-I (148) were recruited and underwent brain magnetic resonance imaging (MRI). Affective
25 symptoms were assessed using Young Mania Rating Scale (YMRS) and Hamilton Depression Rating Scale (HDRS17);
26 the presence of impaired insight was based on the corresponding items of YMRS and HDRS17.27
28 Results. A total of 49.3% reported multiple punctate periventricular WMHs (PWMHs) and 39.9% had deep WMHs
29 (DWMHs). Subjects with lower insight for mania had significantly more PWMHs (54.6% vs 22.2%; p, 0.05) when
30 compared to BD-I patients with higher insight for mania. The presence of PWMHs was independently associated with
31 lower insight for mania: patients who denied illness according to the YMRS were 4 times more likely to have PWMHs
32 (95% CI: 1.21/13.42) than other patients.
33
34 Conclusions. Impaired insight in BD-I is associated with periventricular WMHs. The early identification of BD-I
35 subjects with PWMHs and impaired insight may be crucial for clinicians.
36
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39 Introduction
40 White matter hyperintensities (WMH) are hyperintense
41 signals on T2-weighted magnetic resonance images
42(MRI) that suggest ependymal loss and altered brain
43myelination.1,2 According to their localization, WMHs
44are divided into periventricular white matter hyperin-
45tensities (PWMHs) and deep white matter hyperinten-
46sities (DWMHs) of a predominant vascular aetiology.1
47WMHs are known to be commonly associated with older
48age and risk factors such as arterial hypertension and
49diabetes.3–5 Several studies have suggested that WMHs
50are associated with mood disorders and suicidal behavior
51in different populations (eg, children, young adults, etc).6–8
52Patients with WMHs, particularly with abnormalities in
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53 the prefrontal cortex, amygdala–hippocampus complex,
54 thalamus, and basal ganglia, the integrity of which is
55 necessary for adequate mood regulation,9 may be at a
56 higher risk for developing mood disorders because of
57 possible disruption of neuroanatomic pathways.10
58 Among mood disorders, bipolar disorder (BD),
59 particularly BD type I (BD-I) is a serious mental illness
60 that affects approximately 1% of the adult population.11
61 Several structural changes may be found in the brains of
62 patients with BD, but establishing correlations between
63 neuroimaging findings and measures of illness exposure
64 or age in cross-sectional studies requires caution.12
65 Studies investigating the eventual volumetric
66 abnormalities in some brain structures have indicated
67 possible involvement of the frontal cortex, temporal
68 lobes, basal ganglia, and cerebellum in BD13 and,
69 recently, the subgenual cingulate cortex in both adult14
70 and pediatric populations.15 Table 1 summarizes the
71 most relevant MRI studies of WMHs in adult patients
72 with major psychiatric disorders.
73 WMHs are, no doubt, the most common neuroima-
74 ging finding that have been found in patients with BD,
75 regardless of age.52 Furthermore, there are differences
76 between BD-I and bipolar II (BD-II) patients, as PWMH
77 are more common in BD-I patients compared to BD-II
78 and healthy controls,53,54 indicating that these neuro-
79 imaging findings may be a sensitive and even subtype-
80 selective diagnostic tool.
81 Interestingly, WMH location may be critical in the
82 expression of certain bipolar symptoms. For example,
83 the presence of DWMHs has been associated with
84 poorer response to treatment in bipolar patients, less
85 favorable outcome, and more frequent relapse55; also, a
86 relevant association between increased rates of PWMHs
87 and previous suicide attempts has also been suggested.8
88 Among all clinical manifestations, insight into illness
89 may be widely considered as a relevant factor in coping
90 with and treating patients with BD.56,57 Understanding the
91 neural mechanisms underlying insight and illness aware-
92 ness may have important implications for the development
93 of targeted treatments. Some previous findings have
94 reported an association between WMHs and insight in
95 schizophrenic and/or schizoaffective populations.58–61
96 Our previous studies concerning WMHs found an
97 association between PWMHs and lower depression
98 severity as assessed by the Center for Epidemiologic
99 Studies Depression Scale62; an association between
100 WMHs and older age with late-onset BD63; an associa-
101 tion between affective temperamental profiles, WMHs,
102 and suicidal risk in patients with mood disorders64; an
103 association between WMHs and suicide attempts in
104 patients with bipolar disorders and unipolar depres-
105 sion8,25,65; and an association between deep WMHs and
106 poor prognosis in a sample of patients with late-onset
107 bipolar II disorder.20
108Here we hypothesized that those with WMHs
109compared to those without may be at a higher risk of
110impaired insight as assessed using the item 17 of the
111HDRS17 and item 11 of the YMRS, respectively. The
112present study aimed to evaluate whether the presence of
113WMHs is associated with impaired insight in patients
114with BD-I. To our current knowledge, there are no data
115that link white matter abnormalities and insight in BD-I.
116Methods
117Subjects and study design
118A total of 193 white Caucasian patients consecutively
119admitted to the psychiatric inpatient units of Sant’Andrea
120Hospital and the ‘‘Samadi Clinic’’ in Rome from
121September 2007 to September 2009 participated in
122the study. Inclusion criterion was a Diagnostic and
123Statistical Manual of Mental Disorders, 4th edition, text
124revision (DSM-IV-TR) diagnosis of BD-I.66 Exclusion
125criteria were as follows: other DSM-IV-TR major
126psychiatric disorders; the presence of any neurological
127disorders (eg, epilepsy, multiple sclerosis, Alzheimer’s
128disease, dementia); history of brain concussion; family
129history of dementia; presence of structural MRI findings
130compatible with stroke, including lacunar infarcts or
131other gross brain lesions or malformations; history of
132electroconvulsive therapy in the past 6 months; and
133conditions affecting the ability to participate in the
134assessment, including mental retardation. Based on
135inclusion criteria, 45 (23.3%) patients were not
136included because they had a diagnosis of BD-II. BD-II
137patients who were excluded from the study had similar
138socio-demographic characteristics and did not differ
139significantly from the patients included in the final
140sample with respect to clinical variables (eg, diagnosis
141or history of suicide attempts). The final sample
142consisted of 148 patients (77 men and 71 women).
143The mean age was 47.9 years (SD5 16.1; range: 19–83
144years). Around 13% of the patients reported alcohol
145abuse; 6.1% reported illicit drug abuse, most commonly
146cannabis; and 2.0% reported concurrent abuse of
147alcohol and illicit drugs. Demographic and clinical
148characteristics of the sample are presented in Table 2.
149Clinical and socio-demographic information was taken
150from medical records by 2 researchers independently.
151Current severity of affective symptoms was evaluated
152using the Young Mania Rating Scale (YMRS)67 and
153the Hamilton Depression Rating Scale (HDRS17).68
154Participants were additionally administered the Mini
155International Neuropsychiatric Interview (MINI)69 and
156the Beck Hopelessness Scale (BHS).70,71
157Subjects participated voluntarily in the study, and
158each subject provided written informed consent. The
159study protocol received approval from the local research
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TABLE 1. MRI studies of WMHs in adult patients with major psychiatric disorders
Author (s), references Sample characteristics WMH evaluation Most relevant location of WMHs Main findings and implications
Tighe et al 16 45 BD-I or -II subjects (with or
without PS), and 32 HC
No psychometric instrument Total volume of WMH The mean total volume of WMHs in BD-I patients with psychotic features was significantly higher than
that of HS.
Serafini et al 17 85 CH adult outpatients Modified Fazekas scale Not specified 40% had PWMHs and 98% DWMHs. Patients with PWMHs were more likely to have lower CES-D scores
than patients without; patients with more severe DWMHs were more likely to be older than those with
mild or any DWMHs.
Oudega et al 18 81 elderly MDD patients No psychometric instrument Total volume of WMH No differences in change of MADRS scores were found for WMHs. WMHs did not contribute to poor
response to ECT.
Serafini et al 19 143 BD-I, 42 BD- II, and
62 MDD patients
Modified Fazekas scale Centrum semiovale (24.4%), corona radiate
(20.2%), frontal (17.6%), parietal (15.1%),
temporal, and subcortical (8.4%) DWMHs Q3
48% of patients had PWMHs and 39% had DWMHs. Patients with higher dysthymia and lower
hyperthymia were more likely to have increased DWMHs than patients with lower dysthymia and
higher hyperthymia. Different temperament profiles are associated with differences in the
subcortical brain structures.
Serafini et al 20 54 elderly LO BD patients.
(76% BD-I, 24% BD-II)
Modified Fazekas scale Centrum semiovale (22%), corona radiate
(15%), paratrigonal (6%), frontal (46%),
parietal (24%), and subcortical DWMHs
Confluence of DWMH lesions was found in 17% of the patients whereas confluent PWMHs in 28%. BD-
II patients with DWMHs had a poorer quality of life than BD-I subjects. MRI findings of DWMHs could
be a useful biological predictor of severity in patients with BD-II.
Gunning-Dixon et al 21 42 elderly non-psychotic MDD
and 25 HC subjects
A semi-automated method WMHs and subcortical nuclei Depressed subjects had greater total WMH burden compared to non-depressed controls. Patients who
failed to remit with escitalopram had significantly greater WMH burden than patients who remitted
and HC. WMHs may confer a vulnerability or perpetuate LL depression.
Ko¨hler et al 22 35 subjects aged $ 60 years
with MDD and 29 HC
Scheltens scale Total volume of WMH (both DWMHs and PWMHs) More severe PWMHs and DWMHs were associated with greater deficits in memory and executive
functions at follow-up compared with HC.
Bae et al 23 24 PD patients and 24
matched HC
Composite Fazekas/Coffey scale Frontal DWMHs A greater severity of total WMH was associated with a diagnosis of PD in a dose-dependent pattern.
WMHs may play a role in the pathogenesis of PD.
Fein et al 24 51 LTAA and 46 HC An automated algorithm DWMHs and PWMHs LTAA had more WMHs than HC. WMHs increase with age in LTAA. WMH load was independently
associated with alcohol burden and age.
Pompili et al 25 99 patients: 40.4% BD-I, 21.2%
BD-II, and 38.4% MDD
Modified Fazekas scale Corona radiate (N5 10), centrum semiovale
(N5 6), and frontal subcortical WM (N5 18)
27.3% showed PWMHs, 36.4% DWMHs, and 14.1% of patients had WMHs in both locations. Subjects
with PWMHs were more likely to have attempted suicide than individuals without PWMHs, even after
controlling for potential confounding variables
Sheline et al 26 83 LL depression subjects and
32 HC
Modified Fazekas scale Superior/inferior longitudinal, and fronto-
occipital/uncinate fasciculus, extreme capsule
Depressed subjects had greater WMHs in the investigated brain regions. Whole brain WMHs correlated
with executive functions in depressed subjects; whole brain WM correlated with episodic memory,
processing speed, and executive functions.
Regenold et al 27 20 BP, 15 SCH patients, and
15 with TNS
An automatic volume computation DWMHs BD (and not schizophrenic) patients had significantly greater volumes of DWMHs compared to
neurologic controls. Treatment resistance and poor outcome correlated significantly with DWMH
volume in BD subjects.
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Table 1. Continued
Author (s), references Sample characteristics WMH evaluation Most relevant location of WMHs Main findings and implications
Takahashi et al 28 52 MD patients and 14 HC Modified Fazekas scale Bilateral frontal areas and the left
parieto-occipital region
LO affective disorder patients showed higher ratings of DWMHs than EO patients. Significant
between-group differences were detected in the investigated brain regions.
Zanetti et al 29 129 individuals with FEP and
102 controls
Scheltens scale Total volume of WMH There were no statistically significant between-group differences in WMH frequency or severity scores.
Iosifescu et al 30 65 MDD patients Modified Fazekas scale Subcortical and total WMHs After logistic regression analyses, MDD with anger attacks was associated with higher severity of
subcortical WMHs and total WMHs.
Pompili et al 8 65 AD patients (44.6% with
prior SA)
Modified Fazekas scale Not specified After logistic regression analyses, the prevalence of WMHs was significantly higher in subjects with
past SA. WMHs might be useful biological markers of suicidality.
Patankar et al 31 50 LO MDD patients and
35 HC
Scheltens scale Basal ganglia 29 patients were responders, and 21 non-responders to monotherapy. Subjects with greater VRS
dilation were more likely to be non-responders than those without.
Bae et al 32 33 MA abusers and 32 HC Modified Fazekas scale DWMHs and PWMHs Male MA abusers had greater severity of DWMHs and PWMHs than female MA and HC. Severity of
DWMHs correlated with cumulative dose of MA inducing brain perfusion deficits.
Iosifescu et al 33 84 MDD patients and matched
HC
Modified Fazekas Scale Subcortical WMHs No significant difference was found in the prevalence of WMHs between the depression and the HC
group. Left-hemisphere subcortical WMHs correlated with lower rates of treatment response.
Anstey et al 34 385 adults with WAU No psychometric instrument Total volume of WMH After regression analyses, WAU was not associated with WMHs.
Jorm et al 35 475 subjects aged 60–64 years Modified Fazekas Scale Frontoparietal and PWMHs Depressive symptoms were related to total brain WMHs but not to basal ganglia hyperintensities (the
association is not significant when adjusted for physical disability and smoking).
Ehrlich et al 7 102 young psychiatric MDD
inpatients
Modified Coffey scale PWMHs After logistic regression analyses, the prevalence of PWMHs was significantly higher in subjects with
past SA compared to those without.
Lin et al 36 37 elderly LL MDD patients,
and 18 HC
Modified Fazekas Scale PWMHs Over 60% of patients had significant WMHs. Relative to HC, patients with LL MDD showed more severe
PWMHs. WMHs were correlated with later onset of depression.
Hickie et al 37 47 MDD patients and 21 HC Modified Fazekas Scale DWMHs There was no difference in lesion severity between patients and HC. After controlling for age, vitamin
B12 levels were predictive of DWMHs in patients with MDD.
Heiden et al 38 31 MDD patients (21
re-assessed after 5 years)
Modified Fazekas Scale Frontal WMHs Subjects with greater extent of WMHs had significantly higher Hamilton Depression Rating Scale
scores, more severe depression at follow-up, and a lower Mini-Mental State Examination score.
Lyoo et al 39 32 patients with CD, 32 with
OD and HC
Composite Fazekas/Coffey scale Frontal WMHs Patients with cocaine dependence had greater severity of DWMHs and insular WMHs than those with
opiate dependence and HC. Cocaine may induce more ischemia via vasoconstriction than opiates.
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Table 1. Continued
Author (s), references Sample characteristics WMH evaluation Most relevant location of WMHs Main findings and implications
Firbank et al 40 29 elderly depressed patients
and 32 HC of similar age
Modified Fazekas Scale Frontal WMHs Depressed subjects had a significantly greater frontal-lobe WM volume than HC.
Taylor et al 41 133 MDD subjects aged 60 years
or older
No psychometric instrument Total volume of WMH After regression analyses, a greater change in WMH volume was significantly associated with a failure
to remit even when controlling for confounding factors.
Breeze et al 42 Over 600 psychiatric patients No psychometric instrument Total volume of WMH Subjects with BD were not more likely to have WMH than other psychiatric patients. Lithium use may be
subtly associated with WMHs.
Agid et al 43 37 MDD patients and 27 age-
and sex-matched HC
No psychometric instrument Basal ganglia, temporal lobe, cerebellum, and
brainstem
Mean volume of WMHs was significantly greater in depressed subjects. Depressed patients with WMHs
in the basal ganglia may represent a clinically distinct at-risk subgroup within MDD.
Taylor et al 44 86 LL depression patients and
47 HC
A semi-automated method Fronto-striatal WMHs A significant association between age and WMHs was found in bilateral frontal and left parietal
regions.
Silverstone et al 45 13 depressed BP patients,
11 unipolar depression, and
19 HC
Modified Fazekas Scale DWMHs More BP patients had higher DWMHs scores than both unipolar patients and HC.
Pillai et al 46 15 bipolar adolescents,
19 with SCH and 16 HC
No psychometric instrument Total volume of WMH WMHs were present in 67% of bipolar patients, 37% of those with schizophrenia and 31% of HC.
Bipolar patients had significantly increased WMHs than HC and schizophrenic subjects.
Ahearn et al 47 20 unipolar subjects with prior
SA matched with those
without
Boyko scale, Coffey scale Subcortical WMHs A trend toward significance in PWMHs between unipolar patients with a history of SA compared to those
without was found.
Rivkin et al 48 12 LO and 10 EO SCH patients,
and 31 HC
Explicit WMH volume Total volume of WMH No significant differences in WMH volume were found between the 3 groups. A trend towards increased
WMH volume in the LO schizophrenia group was also found.
Sachdev et al 49 27 LO and 30 EO SCH patients,
and 34 HC
No psychometric instrument Total volume of WMH LO subjects had more PWMHs and subcortical nuclei WMHs than HC.
Sachdev and Brodaty50 25 LO and 24 EO SCH patients,
and 30 HC
No psychometric instrument Widths of periventricular rims and frontal/
occipital caps
Subjects with LO schizophrenia had greater WMHs than the two other groups. LO schizophrenia patients
had more WMHs in the thalamus than HC. PWMHs had significant negative correlations with
intelligence, memory, and frontal-executive functioning.
Symonds et al 51 30 EO and 24 LO SCH patients,
15 with OP, and 41 HC
A scale similar to the modified
Fazekas
Total volume of WMH There were no significant differences between psychotic patients and HC or EO and LO schizophrenic
subjects in terms of frequency, type, or severity of structural abnormalities.
Note: AD5 affective disorders; BD-I5 bipolar disorder type I; BD-II5 bipolar disorder type II; CD5 cocaine dependence; CH5 chronic headache; DWMHs5 deep WMHs; ECT5 electroconvulsive therapy; EO5 early-onset; FEP5 first-episode psychosis;
HC5 healthy control; LL5 late-life; LO5 late-onset; LTAA5 long-term abstinent alcoholics; MA5methamphetamine; MADRS5Montgomery–Asberg Depression Rating Scale; MDD5major depressive disorder; MRI5magnetic resonance imaging;
OD5 opiate dependence; OP5 other psychoses; PD5 panic disorder; PS5 psychotic symptoms; PWMHs5 periventricular WMHs; SA5 suicide attempts; SCH5 schizophrenia; TNS5 transient neurologic symptoms; VRS5 Virchow Robin spaces; WAU5 weekly
alcohol use; WMHs5 white matter hyperintensities.
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160 ethics review board. Clinical interviews were conducted
161 on average 5 days after admission.
162 Magnetic resonance image acquisition and rating of white
163 matter hyperintensities
164 Brain MRIs were performed using a Siemens Sonata
165 MRI scanner (Erlangen, Germany; 1.5T). The FLAIR
Q5 166 scan sequence was used for WMH measurement (ax: TR
167 10000; TE 125; thickness 5mm; matrix 1443256).
168 Proton density and T2-weighted images were obtained
169 (PD and T2 ax: TR 2870; TE 13/107; thickness 5mm;
170 matrix 1473256) in the axial and the coronal planes.
171 Axial and sagittal T1-weighted images were also obtained
172 (T1 ax: TR 647; TE 17; thickness 5mm; matrix 1283192
173 T1 sag: TR 552; TE 17; thickness 5mm; matrix
174 2313192). The presence of a WMH was assessed by a
175 neuroradiologist who was blind to all clinical information,
176 using the modified Fazekas 4-point rating scale, which
177 describes MRI hyperintensities on an ascending scale of
178 intensity and frequency.72 A second neuroradiologist, who
179 was blind to all clinical information and previous WMH
180 ratings, independently reviewed all MRI films. In the
181 present study, the 4-point assessment of the modified
182 Fazekas scale was collapsed into a dichotomous variable
183 that measured the presence or absence of WMHs. The
184 mean k value for inter-rater reliability for both PWMHs
185 and DWMHs was 0.90.
186 Measures: clinical assessment
187 MINI
188 The MINI is a clinically administered, short, structured
189 interview with high validity and reliability that was
190developed to explore 17 disorders according to the
191Diagnostic and Statistical Manual of Mental Disorders,
1923rd edition, revised (DSM-III-R),73 and is routinely used
193in our unit soon after admission. One section of this
194instrument was developed to assess suicidal risk, it
195includes questions about past and current suicidality.69
196Although the MINI should not be a substitute for a
197psychiatric clinical interview, validation studies confirm
198the validity of this instrument as a reliable tool in
199psychiatry.69 MINI diagnoses were confirmed by clinical
200DSM-IV-TR diagnoses. Clinical diagnoses were assigned
201by a psychiatrist and an attending physician who were
202blind to the results of the MINI and MRI scans.
203BHS
204The BHS is a 20-item scale for measuring attitudes
205about the future.70 Research consistently supports a
206positive relationship between BHS scores and measures
207of depression, suicidal intent, and current suicidal
208ideation.74 The BHS may, therefore, be used as a proxy
209indicator of suicide potential. In the study reported in
2101985, 91 of people who died by suicide had a score $ 9,
211while only 9% of suicide victims had a score , 9,
212establishing the BHS cut-off score as 9 or higher as
213predictive of higher suicide risk.75
214HDRS17 and YMRS
215The HDRS17,68 a 17-item clinician-rated scale, was used
216to evaluate depressive symptom severity. The YMRS is
217an 11-item rating scale for mania that explores manic
218symptoms and is considered the gold standard for
219evaluating the concurrent validity of bipolar mania with
220newer scales.67 The item of the HDRS17 that assesses
TABLE 2. Differences between groups with different levels of insight
BD-I with higher
insight for mania
(N5 18)
BD-I with lower
insight for mania
(N5 130)
T-test
(DF5 146) P,
BD-I with higher
insight for depression
(N5 55)
BD-I with lower
insight for depression
(N5 93)
T-test
(DF5 146) P,
Women 22.2% 51.5% 0.05 43.6% 50.5% 0.26
Age – M± SD 50.06 ± 15.12 47.60 ± 16.25 0.61 0.55 46.93 ± 16.26 48.47 ± 16.05 –0.56 0.57
Suicide attempts 38.9% 43.1% 0.47 38.2% 45.2% 0.47
Lifetime suicidal ideation 55.6% 47.7% 0.35 47.3% 49.5% 0.47
BHS – M± SD 8.17 ± 3.92 9.78 ± 4.73 9.13 ± 4.16 9.86 ± 4.93
BHS $ 9 38.9% 66.2% 0.05 52.7% 68.8% 0.05
PWMHs 22.2% 54.6% 0.01 45.5% 53.8% 0.21
DWMHs 27.8% 41.5% 0.20 45.5% 36.6% 0.19
HDRS16 23.67 ± 8.64 27.05 ± 6.54 –1.98 0.05 25.18 ± 6.98 27.51 ± 6.72 –2.00 0.05
HDRS17 $ 18 83.3% 94.6% – – 90.9% 94.6% – –
YMRS10 8.33 ± 5.69 9.33 ± 8.16 –0.50 0.62 8.84 ± 7.93 9.43 ± 7.90 –0.44 0.66
Note: BHS5 Beck Hopelessness Scale; DWMHs5 deep white matter hyperintensities; HDRS165 sum of items 1–16 of the Hamilton Scale for Depression (item 17 was
excluded to avoid the strong correlation between measures of depression and insight); PWMHs5 periventricular white matter hyperintensities; YMRS105 sum of items 1–10
of the and Young Mania Rating Scale (item 11 was excluded to avoid the strong correlation between measures of mania and insight); mean HDRS total score in the total
sample5 25.4; meanQ4 YMRS total score in the total sample5 8.8.
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221 insight (item 17) is measured on a 3-point Likert-type
222 scale [from 0 (acknowledges being ill and depressed) to
223 2 (denies being ill at all)]. The item of the YMRS that
224 assesses insight (item 11) is measured on a 5-point
225 Likert-type scale [from 0 (present; admits illness; agrees
226 with need for treatment) to 4 (denies any behavior
227 change)]. Both variables were dichotomized, and
228 patients were included in any of the following groups:
229 (1) patients who admitted even only the possibility of
230 being ill at the YMRS (higher insight for mania), and
231 those who denied illness or behavior change (lower
232 insight for mania); (2) patients who admitted to being
233 depressed and ill at the HDRS17 (higher insight for
234 depression) and those who completely denied being ill
235 (lower insight for depression).
236 To avoid the strong correlation between measures of
237 depression/mania and insight, we estimated depressive
238 (HDRS16) and mania (YMRS10) severity by omitting
239 items of the scales measuring insight.
240 Statistical Analysis
241 One-sided Fisher exact tests and t-tests were used for
242 bivariate analyses. All variables that were significant in the
243 bivariate analyses were entered as independent variables
244 into 2 logistic regression analyses with groups with
245 different levels of insight as the criterion. Chi-squared
246 tests (x2), Nagelkerke R2, and –2 Log likelihood statistics
247 are reported as statistics of model fit. Odds ratios (OR) and
248 their 95% confidence intervals (CI) are reported as
249 measures of association. Patients were stratified into
250 2 groups (having similar severity of bipolar illness): those
251 having lower insight (having a . 1 as assessed by YMRS
252 item 11) and those with higher insight (having a # 1 as
253 assessed by YMRS item 11). Among these groups, subjects
254 were subsequently divided in those with lower or higher
255 insight for mania and depression, respectively. All the
256 analyses were performed with the Statistical Package for
257 the Social Sciences (SPSS) for Windows 19.0.
258 Results
259 Clinical characteristics of the sample
260 At the time of assessment, 62.8% of the patients had
261 scores of 9 or higher on the BHS, denoting elevated
262 hopelessness and suicide risk. Approximately 88% and
263 63% of BD-I patients denied being ill according to item
264 11 of the YMRS and item 17 of the HDRS17, respectively.
265 Suicide risk
266 Around 43% of the patients (42.6%) had attempted
267 suicide at least once in the past, and 48.6% of them had
268 reported suicidal ideation.
269MRI findings
270A total of 73 subjects (49.3%) had PWMHs and
27159 (39.9%) had DWMHs. Overall, 41 (27.7%) subjects
272had both PWMHs and DWMHs. Of those with PWMHs,
27349 (67.1%) had multiple punctate lesions, 23 (31.5%)
274had beginning confluency of lesions, and only 1 (1.4%)
275had large confluent lesions as assessed by the modified
276Fazekas scale. Of those with DWMHs, 47 (79.7%) had
277multiple punctate lesions, 10 (16.9%) had beginning
278confluency of lesions, and 2 (3.4%) had large confluent
279lesions.
280Insight ratings
281Groups with different levels of insight differed in several
282variables (see Table 2). BD-I patients with lower insight
283for mania were more frequently women (51.5% vs
28422.2%; p50.05), had significantly more PWMHs
285(54.6% vs 22.2%; p,0.05), significantly higher
286scores on the HDRS16 (27.05±6.54 vs 23.67±8.64;
287t146521.98; p,0.05), and a significantly more frequent
288BHS score $ 9 (66.2% vs 38.9%; p,0.05) when
289compared to BD-I patients with higher insight for mania.
290On the contrary, BD-I patients with higher insight for
291depression differed only for BHS (p, 0.05) and HDRS16
292(t146522.00; p, 0.05) scores. BD-I patients with
293lower insight for depression had greater depressive
294severity (27.51±6.72 vs 25.18±6.98) and more frequently
295had scores of 9 or higher on the BHS (68.8% vs 52.7%).
296Two logistic regression models assessed multivariate
297associations between groups and variables significant at
298the bivariate analysis when controlling for the presence
299of other variables. Both models fit the data well (see
300Table 3). The first model explained 20% of the
301variability of the data, and groups with different levels
302of insight in the YMRS differed significantly only for
303PWMHs (p, 0.05). The presence of PWMHs was
304independently associated with lower insight for mania:
305Patients who denied illness according to the YMRS were
3064 times more likely to have PWMHs (95% CI: 1.21/13.42)
307than other patients.
308The second model explained only 9% of the
309variability of the data, but none of the variables inserted
310in the model was independently associated with lower
311insight for depression (HDRS16: OR5 1.05; p5 0.15;
312BHS$ 9: OR5 2.62; p5 0.07).
313Discussion
314To our knowledge, this was the first study to investigate
315the association between WMHs and insight as assessed
316by 1 item of the YMRS in a population of patients
317with BD-I. Subjects with lower insight for mania had
318significantly more PWMHs when compared to BD-I
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319 patients with higher insight for mania. These results
320 indicate that differences in white matter abnormalities,
321 as assessed using the modified Fazekas scale, are
322 associated with differences in insight levels.
323 The present findings extended some previous results
324 of studies that investigated the association between
325 WMHs and insight in different psychiatric populations
326 (eg, schizophrenic and/or schizoaffective patients).58–61
327 For example, Antonius et al 58 suggested that white matter
328 deficits in fronto-temporal brain regions are linked to
329 symptom unawareness, and reduced white matter integrity
330 in temporal and parietal regions is implicated in the
331 misattribution of symptoms. Similarly, Palaniyappan
332 et al ,60 in a sample of predominantly male subjects, found
333 a significant decrease in right posterior insular area in
334 patients with poor insight relative to healthy controls; a
335 negative correlation between insight and local white
336 matter volume of the right posterior insula; and a positive
337 association between the lower surface area of the right
338 posterior insula and the lower degree of insight.
339 Not all studies, however, reported a relationship
340 between frontal lobe atrophy and impaired insight.
341 Bassitt et al 59 found no significant inverse correlations
342 between insight impairment and gray or white matter
343 volumes in the prefrontal region. Similarly, Rossell
344 et al 61 reported no significant correlations between the
345 whole brain, white and gray matter volumes, and the
346 degree of insight in a sample of 78 male patients with
347 schizophrenia and 36 normal male comparison subjects.
348 According to our results, different levels of insight as
349 assessed by the YMRS are associated with MRI findings.
350 BD-I patients with impaired insight on the YMRS were
351 more likely to have PWMHs. WMHs were observed
352 mostly in the centrum semiovale (24.4%) and corona
353 radiata (20.2%) regions and higher in cortical and
354 subcortical deep frontal (17.6%), parietal (15.1%), and
355temporal (8.4%) areas. These brain regions are involved
356in the regulation of mood and may contribute to the
357emergence of impairments in insight.9,76–82 It is
358unlikely that impairments in insight are related to a
359single brain area. Most likely, symptom unawareness is
360linked to complex abnormalities in the network of
361fronto-temporal brain regions.
362The assumption that some bipolar symptoms might
363be due to vascular-related processes (eg, degenerative
364processes including atherosclerosis, lacunar infarcts,
365atrophic demyelination, and arteriolar hyalinization)83
366that alter the connectivity between these brain struc-
367tures is intriguing and is supported by the observed
368post-stroke emergence of mania.84,85 However, here we
369did not find any association between the presence of
370DWMHs (usually having a vascular etiology) and
371impaired insight; therefore, manic symptoms other than
372impaired insight would be affected by these vascular
373processes as previously reported.64
374The association between bipolar disorder and cardio-
375vascular risk factors, including hypertension, hypercholes-
376terolemia, obesity, and cigarette smoking,86,87 is well
377known. However, our findings did not support this link
378between vascular risk factors and the emergence of manic
379symptoms, because after including PWMHs, DWMHs,
380hypertension, diabetes, total cholesterol, triglycerides, and
381number of daily cigarettes as covariates in our analyses,
382the results did not indicate any significant association.
383In contrast with our previous findings,8,25 our study
384did not currently find any association between PWMHs
385and suicidal behavior as assessed using the BHS.
386However, here we investigated a sample of BD-I
387patients, whereas the previous findings8,25 were found
388in a mixed sample of bipolar and major depressed
389patients. The association between PWMHs and suicidal
390behavior is presumably significant only in some subgroups
TABLE 3. Logistic regression models (groups with different levels of insight as criterion)
95%CI for OR
B S.E. Wald df Sig. OR Lower Upper
Model 1
BD-I with lower insight for mania Women 1.19 0.63 3.53 1 0.06 3.28 0.95 11.35
PWMHs 1.40 0.61 5.18 1 0.05 4.04 1.21 13.42
HDRS16 0.04 0.04 1.26 1 0.26 1.04 0.97 1.12
BHS $ 9 0.61 0.58 1.13 1 0.29 1.85 0.60 5.74
Constant –0.39 0.95 0.16 1 0.69 0.68
Model 2
BD-I with lower insight for depression HDRS16 0.05 0.04 2.09 1 0.15 1.05 0.98 1.13
BHS $ 9 0.96 0.54 3.24 1 0.07 2.62 0.92 7.46
Constant –0.79 0.69 1.31 1 0.25 0.46
Model 1 fit: x245 16.56; P, 0.01; –2 Log likelihood5 93.00; Nagelkerke R
2 5 0.20.
Model 2 fit: x225 6.94; P, 0.05; –2 Log likelihood5 102.63; Nagelkerke R
2 5 0.09.
Note: BHS5 Beck Hopelessness Scale; HDRS165 sum of items 1–16 of the Hamilton scale for depression; PWMHs5 periventricular whiteQ6 matter hyperintensities.
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391 of patients with major affective disorders, such as those
392 with a BD type II or major depression.
393 Overall, these findings provide hypothetical evidence
394 in support of the notion that the presence of PWMHs
395 may significantly predict the presence of impaired
396 insight in subjects with BD-I. Therefore, the presence
397 of PWMHs might be used for grouping those subjects
398 with BD-I who will manifest a more pronounced
399 impairment in insight during hospitalization than other
400 bipolar individuals, which will potentially help to
401 optimize alternative treatment strategies.
402 Limitations
403 The present study must be considered in the light of the
404 following limitations. First, the small sample size did
405 not allow for generalization of the present findings. In
406 addition, all our patients were admitted to a psychiatric
407 hospital, which may indicate more severe affective
408 symptoms and poorer insight at admission compared
409 to that usually found in outpatients. This is a potential
410 confounder of the present results according to some
411 recent studies,88,89 which suggests that, at least at
412 functional level, some white matter abnormalities
413 may be state-related. However, the present sample did
414 not include bipolar subjects with current psychotic
415 symptoms, nor severely depressed/manic patients as
416 confirmed by the HDRS and YMRS mean total scores
417 (see Table 2). Therefore, we sustained that the observed
418 white matter abnormalities in our sample were trait-
419 related rather than state-related features.
420 Also, the present study did not include a formal
421 measure of insight. The measurement of insight through
422 item 11 of the YMRS and item 17 of the HDRS17 may be
423 considered questionable, as the variance is not likely to
424 be high. It is also difficult to make a fair comparison
425 with the one item having a 0–4 range for mania and
426 the other 0–2 for depression. However, our results are
427 in line with those of Shad et al 90 and Ha et al 91 and
428 with other authors,92 which suggests that insight is a
429 multidimensional domain. Factor analytic studies have
430 often identified that different insight dimensions
431 significantly overlap and may be represented by a single
432 component able to explain approximately 80% of the
433 variance.93–96 In addition, it has been demonstrated that
434 a good degree of agreement exists between single- and
435 multiple-item measurement of insight.97
436 Moreover, although all our inpatients were taking
437 psychoactive medications and most had a history of
438 substance abuse, we did not analyze the effects of these
439 variables on insight ratings and image processing.
440 It is reasonable to inquire whether the use of
441 psychotropic medications could influence the presence
442 and maintenance of WMHs. To date, there is no
443evidence that WMH rates could be influenced by the
444use of lithium, tricyclic antidepressants, or antiepileptic
445medications.5,53,98,99 Conversely, findings concerning
446the possible influence of antipsychotic drugs is very
447limited, which suggests that caution should be used
448when interpreting the significance of WM lesions in
449patients with major affective disorders who were treated
450with psychoactive medications. However, most of the
451subjects included in the present sample were at their
452first hospitalization, presumably reflecting a short
453history of exposure to antipsychotic drugs. Also, the
454lack of accounting for the cognitive effects of medica-
455tions was due to the fact that these patients did not
456complete a specific neurocognitive assessment.
457Other methodological issues concern the procedure.
458The MRI studies were of quite low spatial resolution and
459done on only a 1.5T scanner. Studies at 3T and with
460higher resolution would have likely yielded a much higher
461number and extent of WMHs. An analysis to quantify total
462white matter lesion volume would strengthen the findings.
463In addition, diffusion tensor imaging techniques may be
464more sensitive for detecting white matter abnormalities in
465association with mood disorders. Also, although we found
466that WMHs were predominant in some brain regions, we
467could not perform regional analysis showing specific
468regional relationship of WMHs to insight.
469Importantly, although WMHs are frequently found in
470populations of bipolar patients, and different mechan-
471isms are considered in the emergence of WMHs, it is
472possible that WMHs may represent the ‘‘tip of the
473iceberg’’ that might be interpreted as an extreme
474consequence of underlying microstructural processes
475that affect brain connectivity, and which may be more
476specifically investigated using diffusion tensor imaging
477methods. Additionally, the Fazekas rating scale as a
478lesion assessment method was limited because visual
479rating scales, even where details of where lesions occur
480are provided, are a less objective method than many of
481the volumetric methods that are available.
482Conclusions
483More than half of our BD-I patients had PWMHs and a
484significant percentage of them had DWMHs. BD-I
485patients with impaired insight were more likely to have
486PWMHs than those without.
487Prospective additional studies are needed in order to
488provide a better understanding of the biological
489processes that are involved in bipolar illness outcome.
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